Genmab — Februar 2015
-
At aktierne er solgt ved bookbuilding, får mig også til at tro at et bud på genmab er meget langt væk. Havde Novartis ønsket at købe hele genmab, så havde de formentligt overtaget aktierne fra GSK i forbindelse med deres køb af GSK's oncology afdeling, havde andre været interesseret så havde de formentlig forsøgt at købe aktierne direkte af GSK, uden bookbuilding.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind